Gallery of our solutions
Gallery of our solutions
Building on its medical expertise for the benefit of patients and consumers, Pierre Fabre innovates tirelessly to develop an increasingly tailored range, from oncology to dermo-cosmetics.
4M
people use the free Kwit app worldwide. It has already helped 50,000 smokers quit the habit.
13
products, 5 dietary supplements and 8 dermo-cosmetic products make up the Miyé brand, specializing in hormonal balance and well-being.
Caring for cancer* patients.
As a trailblazer in oncology for over 40 years, Pierre Fabre Laboratories helps improve treatments for patients suffering from diseases for which major therapeutic needs remain unmet.
That commitment is illustrated by the availability in Europe since January 2023 of EBVALLO® for the treatment of a rare lymphoproliferative disorder. In December 2023, Pierre Fabre Laboratories won the prestigious Prix Galien award in France for this cell therapy, in the "Advanced Therapy Medicinal Product" category. The Galien award recognizes outstanding recent innovations in the field of medicine.
* Cancer is the leading cause of premature mortality in France, ahead of cardiovascular diseases. In 2023, 433,136 new cancer cases were diagnosed in France. It is estimated that some 3.8 million people in France today have been diagnosed with cancer. Cancer is the second leading cause of death globally, accounting for nearly 10 million deaths every year.
Treating chronic diseases.
Pierre Fabre Laboratories markets a range of drugs covering a broad spectrum of pathologies in the fields of urology, women’s health and rheumatology. As a result, we contribute to the treatment of chronic diseases and deficiencies.
Evidence of our commitment in this area: in 2022, Pierre Fabre signed a licensing agreement with Urovant Sciences for the marketing of vibegron, a key urological drug for the treatment of an overactive bladder, across Europe. Its launch is currently being prepared.
Treating skin diseases.
As experts in the treatment of skin disorders, Pierre Fabre Laboratories develops a host of solutions for dermatological pathologies.
This is the case for atopic dermatitis, psoriasis and acne. Additionally, a new topical formulation was launched by Pierre Fabre in 2023 for actinic keratosis. This cream with 4% Fluorouracil requires just 1 application per day for 4 weeks. The efficacy of this new formula is clinically proven for the treatment of visible lesions and pre- cancerous zones.
A-Derma strengthens its position as a specialist brand for damaged and weakened skin.
Hyaluron Activ BB3 is revolutionizing skin regeneration.
Caring for skin and hair, promoting oral hygiene.
Determined to bring innovative, effective solutions to the market, Pierre Fabre designs and develops dermo-cosmetics and oral hygiene products, working closely with healthcare professionals.
Two examples illustrate this commitment to excellence: the A-Derma Exomega Allergo range and the Hyaluron Activ B3 day cream.
To effectively meet the needs of patients suffering from atopy, and in particular the 30% who are allergic, A-Derma has enhanced its Exomega range with Allergo: a sterile cosmetics emollient salve that soothes dryness, redness and irritation. In just 2 days, this balm reduces itching on eyelids and dry skin (prone to atopic eczema) by 77%.
Another example, developed through Pierre Fabre Laboratories' cutting-edge dermo-cosmetics expertise, is the Hyaluron Activ B3 day cream by Eau Thermale Avène, which with its innovative, revolutionary approach to anti-aging. This dermo-cosmetic product, concentrated in Hyaluronic Acid and Niacinamide, acts on the cause of aging to firm up skin and correct wrinkles. The Hyaluron Activ B3 range is revolutionizing skin regeneration: +85% cell regeneration*, wrinkles corrected from 15 days**. It is thus affirming its position as the leader in the dermo-cosmetics market, ranking No. 1 in the anti-aging segment***. Whilst in the field of oral hygiene, Pierre Fabre remained market leader in pharmacies**** whithin France and Europe.
*ex-vivo test
**Perceived results, self-assessment, 65 users
***IQVIA — Pharmatrend PharmaOne - anti-aging/anti-wrinkle cream market (82B5) in pharmacies in France - Year to date October 2023 – value
****Source: IQVIA December 2023
Treating everyday ailments.
Sore throats, urinary infections, painful periods: Pierre Fabre offers a broad range of family health treatments available from pharmacies.
To provide better support for quitting smoking, for example, the company signed a partnership with the Kwit app in October 2023. The aim is to give the app which helps people quit smoking, a new interface to simplify the way patients are treated by healthcare professionals, and improve follow-up via a shared dashboard.
Additionally, the company acquired a stake in the startup MiYé in September 2023. MiYé supports women from puberty to menopause, developing the most natural solutions to care for all skin types affected by hormonal changes.
